Certolizumab pegol, a pegylated anti‐TNF‐α antagonist, caused de novo‐onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis
Gespeichert in:
| Veröffentlicht in: | Journal of dermatology 2017-06, Vol.44 (6), p.723-724 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 724 |
|---|---|
| container_issue | 6 |
| container_start_page | 723 |
| container_title | Journal of dermatology |
| container_volume | 44 |
| creator | Koizumi, Haruka Tokuriki, Atsushi Oyama, Noritaka Ido, Hideki Sugiura, Kazumitsu Akiyama, Masashi Hasegawa, Minoru |
| description | |
| doi_str_mv | 10.1111/1346-8138.13530 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_1346_8138_13530</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JDE13530</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2490-468d2fdb2955962dfe735e68bef879c29cccfb37a2a6a3d83f9ef0ad566e64003</originalsourceid><addsrcrecordid>eNqFkUtSxCAQhilLS8fH2p3FAYySEPJYWuO7LN3oOkWSZgaLCSkgTo0rj-BV3HsGD-FJBKNuZQE0fP9P043QfkyOYj-OY5pmURHT4iimjJI1NPk7WUcTQgsWJSnJt9C2tY-EJCWLySbaSnJWlilhE_Q-BeO0ks_Dgte4h5lWh5iHzUpxBy3mnZOfL6_3t-d-_ngLMZ_pTlp3iBs-WI-0gDv9pP297iw43HO10L0KpMH9YN2gtJUWC62UXnpBvcIz6MBw_64PRySwVhvJAyq7kAR3EjqHl9LNsZmDT9Fp6VMybm6kk3YXbQiuLOz9rDvo4fzsfnoZ3dxdXE1PbqImSUsSpVnRJqKt_e9ZmSWtgJwyyIoaRJGXTVI2TSNqmvOEZ5y2BRUlCMJblmWQpYTQHXQ8-jZGW2tAVL2RC25WVUyq0IcqVL0KVa----AVB6OiH-oFtH_8b-E9wEZgKRWs_vOrrk_PRuMv1p-cQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Certolizumab pegol, a pegylated anti‐TNF‐α antagonist, caused de novo‐onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Koizumi, Haruka ; Tokuriki, Atsushi ; Oyama, Noritaka ; Ido, Hideki ; Sugiura, Kazumitsu ; Akiyama, Masashi ; Hasegawa, Minoru</creator><creatorcontrib>Koizumi, Haruka ; Tokuriki, Atsushi ; Oyama, Noritaka ; Ido, Hideki ; Sugiura, Kazumitsu ; Akiyama, Masashi ; Hasegawa, Minoru</creatorcontrib><identifier>ISSN: 0385-2407</identifier><identifier>EISSN: 1346-8138</identifier><identifier>DOI: 10.1111/1346-8138.13530</identifier><identifier>PMID: 27599405</identifier><language>eng</language><publisher>England</publisher><subject>Administration, Oral ; Aged ; Antirheumatic Agents - adverse effects ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - immunology ; Certolizumab Pegol - adverse effects ; Disease Progression ; Etretinate - administration & dosage ; Female ; Foot ; Hand ; Humans ; Keratolytic Agents - administration & dosage ; Psoriasis - chemically induced ; Psoriasis - drug therapy ; Psoriasis - immunology ; Psoriasis - pathology ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Tumor Necrosis Factor-alpha - immunology</subject><ispartof>Journal of dermatology, 2017-06, Vol.44 (6), p.723-724</ispartof><rights>2016 Japanese Dermatological Association</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2490-468d2fdb2955962dfe735e68bef879c29cccfb37a2a6a3d83f9ef0ad566e64003</citedby><cites>FETCH-LOGICAL-c2490-468d2fdb2955962dfe735e68bef879c29cccfb37a2a6a3d83f9ef0ad566e64003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1346-8138.13530$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1346-8138.13530$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27599405$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koizumi, Haruka</creatorcontrib><creatorcontrib>Tokuriki, Atsushi</creatorcontrib><creatorcontrib>Oyama, Noritaka</creatorcontrib><creatorcontrib>Ido, Hideki</creatorcontrib><creatorcontrib>Sugiura, Kazumitsu</creatorcontrib><creatorcontrib>Akiyama, Masashi</creatorcontrib><creatorcontrib>Hasegawa, Minoru</creatorcontrib><title>Certolizumab pegol, a pegylated anti‐TNF‐α antagonist, caused de novo‐onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis</title><title>Journal of dermatology</title><addtitle>J Dermatol</addtitle><subject>Administration, Oral</subject><subject>Aged</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Arthritis, Rheumatoid - immunology</subject><subject>Certolizumab Pegol - adverse effects</subject><subject>Disease Progression</subject><subject>Etretinate - administration & dosage</subject><subject>Female</subject><subject>Foot</subject><subject>Hand</subject><subject>Humans</subject><subject>Keratolytic Agents - administration & dosage</subject><subject>Psoriasis - chemically induced</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis - immunology</subject><subject>Psoriasis - pathology</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><issn>0385-2407</issn><issn>1346-8138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtSxCAQhilLS8fH2p3FAYySEPJYWuO7LN3oOkWSZgaLCSkgTo0rj-BV3HsGD-FJBKNuZQE0fP9P043QfkyOYj-OY5pmURHT4iimjJI1NPk7WUcTQgsWJSnJt9C2tY-EJCWLySbaSnJWlilhE_Q-BeO0ks_Dgte4h5lWh5iHzUpxBy3mnZOfL6_3t-d-_ngLMZ_pTlp3iBs-WI-0gDv9pP297iw43HO10L0KpMH9YN2gtJUWC62UXnpBvcIz6MBw_64PRySwVhvJAyq7kAR3EjqHl9LNsZmDT9Fp6VMybm6kk3YXbQiuLOz9rDvo4fzsfnoZ3dxdXE1PbqImSUsSpVnRJqKt_e9ZmSWtgJwyyIoaRJGXTVI2TSNqmvOEZ5y2BRUlCMJblmWQpYTQHXQ8-jZGW2tAVL2RC25WVUyq0IcqVL0KVa----AVB6OiH-oFtH_8b-E9wEZgKRWs_vOrrk_PRuMv1p-cQA</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Koizumi, Haruka</creator><creator>Tokuriki, Atsushi</creator><creator>Oyama, Noritaka</creator><creator>Ido, Hideki</creator><creator>Sugiura, Kazumitsu</creator><creator>Akiyama, Masashi</creator><creator>Hasegawa, Minoru</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201706</creationdate><title>Certolizumab pegol, a pegylated anti‐TNF‐α antagonist, caused de novo‐onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis</title><author>Koizumi, Haruka ; Tokuriki, Atsushi ; Oyama, Noritaka ; Ido, Hideki ; Sugiura, Kazumitsu ; Akiyama, Masashi ; Hasegawa, Minoru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2490-468d2fdb2955962dfe735e68bef879c29cccfb37a2a6a3d83f9ef0ad566e64003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Arthritis, Rheumatoid - immunology</topic><topic>Certolizumab Pegol - adverse effects</topic><topic>Disease Progression</topic><topic>Etretinate - administration & dosage</topic><topic>Female</topic><topic>Foot</topic><topic>Hand</topic><topic>Humans</topic><topic>Keratolytic Agents - administration & dosage</topic><topic>Psoriasis - chemically induced</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis - immunology</topic><topic>Psoriasis - pathology</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koizumi, Haruka</creatorcontrib><creatorcontrib>Tokuriki, Atsushi</creatorcontrib><creatorcontrib>Oyama, Noritaka</creatorcontrib><creatorcontrib>Ido, Hideki</creatorcontrib><creatorcontrib>Sugiura, Kazumitsu</creatorcontrib><creatorcontrib>Akiyama, Masashi</creatorcontrib><creatorcontrib>Hasegawa, Minoru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koizumi, Haruka</au><au>Tokuriki, Atsushi</au><au>Oyama, Noritaka</au><au>Ido, Hideki</au><au>Sugiura, Kazumitsu</au><au>Akiyama, Masashi</au><au>Hasegawa, Minoru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Certolizumab pegol, a pegylated anti‐TNF‐α antagonist, caused de novo‐onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis</atitle><jtitle>Journal of dermatology</jtitle><addtitle>J Dermatol</addtitle><date>2017-06</date><risdate>2017</risdate><volume>44</volume><issue>6</issue><spage>723</spage><epage>724</epage><pages>723-724</pages><issn>0385-2407</issn><eissn>1346-8138</eissn><cop>England</cop><pmid>27599405</pmid><doi>10.1111/1346-8138.13530</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0385-2407 |
| ispartof | Journal of dermatology, 2017-06, Vol.44 (6), p.723-724 |
| issn | 0385-2407 1346-8138 |
| language | eng |
| recordid | cdi_crossref_primary_10_1111_1346_8138_13530 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Oral Aged Antirheumatic Agents - adverse effects Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology Certolizumab Pegol - adverse effects Disease Progression Etretinate - administration & dosage Female Foot Hand Humans Keratolytic Agents - administration & dosage Psoriasis - chemically induced Psoriasis - drug therapy Psoriasis - immunology Psoriasis - pathology Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor-alpha - immunology |
| title | Certolizumab pegol, a pegylated anti‐TNF‐α antagonist, caused de novo‐onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T00%3A25%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Certolizumab%20pegol,%20a%20pegylated%20anti%E2%80%90TNF%E2%80%90%CE%B1%20antagonist,%20caused%20de%20novo%E2%80%90onset%20palmoplantar%20pustulosis%20followed%20by%20generalized%20pustular%20psoriasis%20in%20a%20patient%20with%20rheumatoid%20arthritis&rft.jtitle=Journal%20of%20dermatology&rft.au=Koizumi,%20Haruka&rft.date=2017-06&rft.volume=44&rft.issue=6&rft.spage=723&rft.epage=724&rft.pages=723-724&rft.issn=0385-2407&rft.eissn=1346-8138&rft_id=info:doi/10.1111/1346-8138.13530&rft_dat=%3Cwiley_cross%3EJDE13530%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27599405&rfr_iscdi=true |